Results from a first six-case cohort preliminary phase I clinical study (NCT03198546) in advanced HCC/PC/ovarian carcinoma (OC) patients with glypican-3 (GPC3) or MSLN expression have been published recently and show encouraging results: two complete responses (CR), two partial responses (PR) and 2 steady diseases (SD). Here, MSLN is linked to ovarian carcinoma.